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I.

INTRODUCTION

Advances in modern medicine and medical technology have
led to tremendous success in treating formerly untreatable
diseases, including many types of cancer.1 This has resulted in
the extension of patients’ lives for years, and sometimes even for
decades.2
The cornerstone behind these advances are
treatments based on an understanding of the molecular basis of
the diseases. For example, immuno-oncology, which uses the
body’s own immune system to combat cancer, has proven to be a
promising technique and has achieved great distinction over the
last decade. In order to harness the power of immuno-oncology,
scientists must be able to find the correct molecular targets
located on the surface of the cancer cells in each individual
patient.3 Diagnostic tests are used to find these molecular
1. This Note is dedicated to my mother, Dr. Anne Rybicki, who passed
away in October 2019 from breast cancer.
2. See Results from Clinical Trials with Keytruda: Metastatic Melanoma,
KEYTRUDA, https://www.keytruda.com/melanoma/monotherapy-clinical-trialresults/ (last visited Oct. 26, 2021).
3. See Inês Martins, About Immuno-Oncology, IMMUNO-ONCOLOGY NEWS,
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targets.4
However, the patents that protect these tests’
intellectual property, known as “diagnostic method patents,” are
currently under attack due to a recent change in Supreme Court
precedent.5 Beginning in 2012 with the Supreme Court’s
decision in Mayo Collaborative Services v. Prometheus
Laboratories, Inc., the ability to patent diagnostic method
claims6 has been diminished under a patent-eligibility exception
called the “laws of nature.”7 This has often resulted in
reductions in the commercial value of diagnostic tests and
imposed a chilling effect on innovation. The adverse effects of
this change in the patentability of diagnostic methods are felt by
both the innovators in the biotechnology sector as well as the
patients whose diseases would benefit from advances in
immuno-oncology discoveries.
This Note argues that diagnostic method patent claims,
which are at the forefront of molecular medicine, must be
afforded proper legal protection by the United States court
system. Part II of this Note discusses the central role of
immuno-oncology in the development of life-saving therapeutics.
Part III of this Note explains the critical link between advances
in immuno-oncology and the patentability of diagnostic method
patent claims. Part IV describes the issues related to securing
diagnostic method patents under 35 U.S.C. § 101. Part V
discusses the evolution of Supreme Court precedent regarding
patent-eligibility under 35 U.S.C. § 101 and how lower courts
have struggled to interpret § 101 under Supreme Court
precedent. Part VI explores the different remedies stakeholders
have taken in response to the Supreme Court precedent and its
inconsistent interpretations by various tribunals. Part VII
argues that in a world where rapid changes in medical
technology can provide dramatic opportunities to meaningfully
decrease patient morbidity and mortality—particularly in the
https://immuno-oncologynews.com/immuno-oncology/ (last visited Nov. 17,
2021).
4. See Margarita Udall et al., PD-L1 Diagnostic Tests: A Systematic
Literature Review of Scoring Algorithms and Test-Validation Metrics,
DIAGNOSTIC
PATHOLOGY
(Feb.
2018),
https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-0180689-9.
5. See discussion infra Part V.
6. A claim is the part of the patent that describes the invention.
7. See discussion infra Part V.
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area of cancer therapeutics—it is necessary for the law and
technology to collaborate in order to allow for the continued
stimulation of innovation.
II.

WHAT IS IMMUNO-ONCOLOGY & WHY IS IT IMPORTANT?

“Immuno-oncology is the study and development of
treatments that take advantage of the body’s immune system to
fight cancer.”8
These treatments, which are called
immunotherapy, are important because they have the potential
to revolutionize modern cancer care.9 Unlike the standard “cut,
poison, burn” regimen that most people associate with
combating cancer, immuno-oncology harnesses the power of the
body’s best defense to fight against these diseases.
The immune system is comprised of a network of different
organs, cells, and proteins that protect the body against foreign
substances such as bacteria, viruses, fungi, and toxins.10 It does
this by distinguishing unfamiliar “non-self” molecules from the
body’s own “self” molecules based on the biological markers
present on their surfaces, called antigens.11 Once these “nonself” molecules are identified, an immune response is triggered,
causing different actors within the immune system to attack,
kill, and clear them away.12 This is called immunosurveillance.13
However, issues arise when the immune system is unable to
differentiate between “self” and “non-self” molecules.14 For
example, during an allergic reaction, the body registers
harmless allergens such as dust, pollen, or peanuts as
threatening, and in response produces increased levels of “self”
antibodies called Immunoglobulin E (IgE), which causes an
overreaction by the immune system that results in
8. Understanding the Role of Immuno-Oncology in Treating Cancer,
CANCERCARE
4
(2020)
https://www.cancercare.org/publications/285understanding_the_role_of_immuno-oncology_in_treating_cancer).
9. See What Is Cancer Immunotherapy?, CANCER RSCH. INST.,
https://www.cancerresearch.org/immunotherapy/what-is-immunotherapy
(Oct. 2020).
10. See How Does the Immune System Work?, INST. FOR QUALITY &
EFFICIENCY IN HEALTH CARE, https://www.ncbi.nlm.nih.gov/books/NBK279364/
(Apr. 23, 2020).
11. Martins, supra note 3.
12. Id.
13. See id.
14. Id.
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inflammation, and in severe cases anaphylaxis.15 Another
example of when the immune system encounters confusion is
when cancer develops. Cancer cells are “self” cells that have
genetically mutated over time, turning them from healthy cells
into malignant cells.16 These mutations can be due to genetic
inheritance, old age, or exposure to something damaging in the
environment, such as cigarette smoke or free radicals.17 After a
cancer cell mutates, it begins to divide rapidly and form tumors
throughout the body.18 Sometimes the immune system can
detect this abnormal division and transmit an alert (i.e.,
inflammation in the underarm that is produced in response to
cancer cells located in the lymph node). However, most of the
time cancer cells can evade immunosurveillance by “[u]sing
deceptive signaling” that makes them appear as “self” cells when
they are anything but that.19 One way they do this is by
expressing antigens similar to those found on normal cells,
essentially blending in with their surroundings.20 This causes
the cancer cells to grow unchecked in the body because the
immune system cannot identify the threat. Therefore, cancer is
usually not discovered until treatment is already critical.
Both modern technology and scientific researchers’
understanding of the immune system have advanced
tremendously over the past few decades, leading to new and
powerful tools to combat cancer. Some of these tools include
immunotherapy techniques such as chimeric antigen receptor Tcell (“CAR-T”) therapy, immune checkpoint inhibitors, oncolytic
virotherapy, vaccines, and monoclonal antibody (“mAb”)
15. See Allergic Reaction Defined, AM. ACAD. OF ALLERGY ASTHMA &
IMMUNOLOGY,
https://www.aaaai.org/tools-for-the-public/allergy,-asthmaimmunology-glossary/allergic-reaction-defined (last visited Nov. 18, 2021).
16. See How Cancer Starts, Grows and Spreads, CAN. CANCER SOC’Y,
http://www.cancer.ca/en/cancer-information/cancer-101/what-is-cancer/howcancer-starts-grows-and-spreads/?region=qc (last visited Nov. 18, 2021).
17. See id.
18. See id.
19. CTCA, How Does the Immune System Work? When It Comes to Cancer,
It’s Complicated, CANCER TREATMENT CTRS. OF AM. (Oct. 18, 2017),
https://www.cancercenter.com/community/blog/2017/10/how-does-theimmune-system-work-when-it-comes-to-cancer-its-complicated.
20. See Catch Me If You Can: Finding Cancer Cells that Hide in Plain
Sight, DANA-FARBER CANCER INST. (Aug. 8, 2018), https://blog.danafarber.org/insight/2017/06/catch-me-if-you-can-finding-cancer-cells-that-hidein-plain-sight.
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therapy.21 Immunotherapy is increasingly important because it
can “effectively treat cancer in a non-toxic way as compared to
conventional treatment options.”22 For example, chemotherapy,
which involves the administration of toxic drugs into the body,
kills both healthy and malignant cells, subsequently causing
immunosuppression and a multitude of unwanted side effects
(e.g., hair loss, fatigue, and nausea).23 Not only are these
conventional methods poisonous, but they are also painful.24
Radiation, which consists of burning away the cancer cells, and
surgery, which requires the removal of the cancer cells from the
affected organs, are uncomfortable and unreliable choices.25 In
contrast, “the immune system is the only natural and the least
toxic tool for fighting any kind of disease within the body[,]”
including cancer.26
Additionally, immunotherapy has the power to transform
cancer care due to how personalized it is.27 In recent years,
scientific research has shown that “no two patients’ cancers are
exactly the same,” which has resulted in inconsistent response
rates to traditional treatment options.28 This is because every
individual has a specific genetic makeup, and so the cancer cells
that form within their body are unique to them.29 Thus, the
oversimplified model of chemotherapy, radiation, and surgery
often leads to ineffective results.30
Further, due to the
complexity of cancer and its ability to mask itself and silently
spread throughout the body in a process known as metastasis,
the standard “cut, poison, burn” routine may soon prove to be a
thing of the past.31 The ability to personalize a patient’s medical
21. See Types of Cancer Immunotherapy, CANCER RSCH. UK (Jan. 20,
2021),
https://www.cancerresearchuk.org/about-cancer/cancer-ingeneral/treatment/immunotherapy/types.
22. Martins, supra note 3.
23. See id.
24. See id.
25. See id.
26. Id.
27. See What Is Cancer Immunotherapy?, supra note 9.
28. Paulina Krzyszczyk et al., The Growing Role of Precision and
Personalized Medicine for Cancer Treatment, 6 TECHNOLOGY 79, 80 (2018).
29. See What Is Cancer?, NAT’L CANCER INST. (May 5, 2021),
https://www.cancer.gov/about-cancer/understanding/what-is-cancer.
30. See Krzyszczyk et al., supra note 28.
31. See
What
Is
Metastasis?,
CANCER.NET
(Mar.
2019),
https://www.cancer.net/navigating-cancer-care/cancer-basics/what-
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treatment based on the “specific characteristics of
[an]
individual[]” or “the genetic profile of an individual’s tumor” has
already been recognized as a smarter, more efficient, and more
precise method of oncological medicine, and has even received
support from the FDA.32
One example of an immuno-oncology success story is
Keytruda. Keytruda is an FDA-approved mAb immunotherapy
medicine that treats various cancers such as melanoma and nonsmall cell lung cancer (“NSCLC”) by helping the immune system
detect and fight against cancer.33 Instead of attacking cancer
directly, Keytruda assists the body in distinguishing malignant
“non-self” cells that have tried to trick the immune system by
hiding behind a “self” cell disguise.34 Specifically, Keytruda is
an “anti-PD-1 inhibitor,”35 meaning that it “blocks the activity of
a molecule called PD-1,” (“[p]rogrammed cell death protein 1”36),
which some cancer cells exploit to avoid immunosurveillance.37
PD-1 is a protein expressed on the surface of activated Tlymphocytes, which are one of the many actors within the
immune system.38 PD-1 naturally binds to PD-L1 (“programmed
cell death receptor ligand 1”39), a protein often expressed on
healthy muscles and nerve cells, but sometimes on stealthy
cancerous cells as well.40 When PD-1 and PD-L1 bind, a signal
is sent that inactivates the T-lymphocytes from destroying what

metastasis.
32. Precision
Medicine,
U.S.
FDA
(Sept.
27,
2018),
https://www.fda.gov/medical-devices/vitro-diagnostics/precision-medicine.
33. See Frequently Asked Questions About Keytruda, KEYTRUDA,
https://www.keytruda.com/keytruda-faq/ (last visited Nov. 22, 2021).
34. See id.
35. Pembrolizumab
(Keytruda®),
MELANOMA
RSCH.
ALL.,
https://www.curemelanoma.org/patient-eng/melanomatreatment/immunotherapy/pembrolizumab-keytruda-/ (Aug. 2021).
36. Arlene H. Sharpe & Kristen E. Pauken, The Diverse Functions of the
PD1 Inhibitory Pathway, 18 NATURE REVS. IMMUNOLOGY 153, 153 (2018).
37. Pembrolizumab (Keytruda®), supra note 35.
38. See Han Yao et al., Cancer Cell-Intrinsic PD-1 and Implications in
Combinatorial Immunotherapy, FRONTIERS IN IMMUNOLOGY (July 30, 2018),
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01774/full.
39. Akintunde Akinleye & Zoaib Rasool, Immune Checkpoint Inhibitors of
PD-L1 As Cancer Therapeutics, 12 J. HEMATOLOGY & ONCOLOGY 1, 1 (2019).
40. See Erik Thunnissen & Egbert F. Smit, Nonsmall-Cell Cancers of the
Lung: Pathology and Genetics, in ENCYCLOPEDIA OF CANCER (Paolo Boffetta &
Pierre Hainaut, eds., 3d ed. 2019).
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looks like a normal cell.41 This PD-1/PD-L1 interaction allows
cancer cells to escape “immune detection and elimination.”42
Keytruda works to block this interaction.43 By blocking PD-1
from binding to PD-L1, cancer cells become susceptible to attack
by the immune system and die.44 The use of Keytruda has
reduced the risk of metastatic melanoma progression “by 43%
compared to chemotherapy[,]”45 and for NSCLC patients with
high levels of PD-L1, Keytruda reduced the risk of death “by 58
percent.”46 For biotechnology companies, scientific researchers,
oncologists, cancer patients, and patients’ families, these results
are “game-changing.”47 Keytruda demonstrates the potential of
immuno-oncology to extend the lives of cancer patients who
previously had a poor prognosis, and the field is rapidly
becoming recognized as a primary therapy for a variety of
cancers.
III.

IMMUNO-ONCOLOGY & THE LINK TO
DIAGNOSTIC METHOD PATENTS

Diagnostic tests are used to detect immune pathways such
as PD1/PD-L1.48 A diagnostic test is “[a] type of test used to help
diagnose a disease or condition.”49 With respect to immunooncology, diagnostic tests are used to locate certain antigens on
the surface of cancer cells, called “cancer biomarkers.”50
41. See Understanding PD-L1, GENENTECH (May 16, 2016),
https://www.gene.com/stories/understanding-pd-11.
42. Cancer Immunotherapy and the PD-1/PDL-1 Checkpoint Pathway,
ABCAM,
https://www.abcam.com/cancer/cancer-immunotherapy-and-thepd1pdl1-pathway (last visited Nov. 24, 2021).
43. See Pembrolizumab (Keytruda®), supra note 35.
44. See id.
45. Results from Clinical Trials with Keytruda, KEYTRUDA,
https://www.keytruda.com/melanoma/monotherapy-clinical-trialresults/#compare-chemotherapy (last visited Nov. 24, 2021).
46. Jamie Reno, Keytruda Performs Well in Latest Lung Cancer Clinical
Trials, HEALTHLINE (Apr. 27, 2018), https://www.healthline.com/healthnews/keytruda-performs-well-in-latest-lung-cancer-clinical-trials#1.
47. Id.
48. See Udall et al., supra note 4.
49. NCI Dictionary of Cancer Terms: Diagnostic Test, NIH NAT’L CANCER
INST.,
https://www.cancer.gov/publications/dictionaries/cancerterms/def/diagnostic-test (last visited Nov. 24, 2021).
50. Klervi Even-Desrumeaux, et al., State of the Art in Tumor Antigen and
Biomarker Discovery, 3 CANCERS (SPECIAL ISSUE) 2554, 2555 (2011).
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“[C]ancer biomarkers can be defined as markers produced either
by the tumor itself or by other tissues, in response to the
presence of cancer or other associated conditions, such as
inflammation.”51 Once identified, these biomarkers can be used
in a variety of ways, including to diagnose cancer, monitor a
patient’s response to treatment, and create new and innovative
immunotherapies based on a particular molecular pathway.52
Another example of a cancer-related diagnostic test is the
test for the BRCA1 and BRCA2 gene mutations.53 These
mutations are associated with breast cancer.54 Although only
roughly “0.25% of the population carry a mutated BRCA1 or
BRCA2 gene[],” women who carry the BRCA mutations have a
significantly “higher lifetime risk” of developing breast cancer.55
Studies show that “55–65% of women with the BRCA1 mutation
will develop breast cancer before age 70” and “[a]pproximately
45% of women with the BRCA2 mutation will develop breast
cancer by age 70.”56 Moreover, “[a]bout 1 in 8 U.S. women . . .
will develop . . . breast cancer over the course of her lifetime.”57
The diagnostic test for BRCA1 and BRCA2 has significantly
increased the lifespan of carriers of this deadly gene.
Due to the tremendous health benefits of identifying cancer
biomarkers, the commercial value of diagnostic tests is
significant. The promise of profitability, in turn, incentivizes
biotechnology companies and other key scientific investigators
to continue the search for additional tumor antigens, and thus
creates the potential for new immunotherapy treatments.
However, a recent change in Supreme Court precedent has
thrown into disarray the patentability of such discoveries. In
2012, the Supreme Court handed down its unanimous ruling in
51. Id. at 2555.
52. See id.
53. See Genetic Testing for Breast Cancer, NAT’L BREAST CANCER FOUND.,
INC., https://www.nationalbreastcancer.org/genetic-testing-for-breast-cancer
(last visited Nov. 25, 2021).
54. See BRCA Gene Test for Breast and Ovarian Cancer Risk, MAYO
CLINIC (Aug. 12, 2021), https://www.mayoclinic.org/tests-procedures/brcagene-test/about/pac-20384815.
55. BRCA: The Breast Cancer Gene, NAT’L BREAST CANCER FOUND., INC.
(Apr. 15, 2020), https://www.nationalbreastcancer.org/what-is-brca.
56. Id.
57. U.S.
Breast
Cancer
Statistics,
BREASTCANCER.ORG,
https://www.breastcancer.org/symptoms/understand_bc/statistics (Feb. 4,
2021).
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Mayo Collaborative Services v. Prometheus Laboratories, Inc.,
holding that diagnostic methods for detecting cancer biomarkers
were unpatentable under 35 U.S.C. § 101, the section of the law
that determines the subject matter eligibility of patents.58 The
Court held that such diagnostic method patents are not
patentable because they “effectively claim natural laws or
natural phenomena” (i.e., seek to patent processes that occur
effortlessly in nature).59 This ruling, and several Supreme Court
cases that followed it, have created new challenges for the
scientists and companies that are developing therapies based on
immuno-oncology.
IV.

35 U.S.C. § 101 AND THE “LAWS OF NATURE”

Under 35 U.S.C. § 101, “[w]hoever invents or discovers any
new and useful process, machine, manufacture, or composition
of matter, or any new and useful improvement thereof, may
obtain a patent therefor, subject to the conditions and
requirements of this title.”60 This statute, which was most
recently revised in 2019, “limit[s] the subject matter that is
eligible for patenting.”61 In order to successfully obtain a patent,
the claimed invention must meet the United States Patent and
Trademark Office’s (“USPTO”) two criteria for subject matter
eligibility.62 According to the USPTO, the first criteria is that
“the claimed invention must be to one of the four statutory
categories . . . of invention that Congress deemed to be the
appropriate subject matter of a patent: processes, machines,
manufactures and compositions of matter.”63 The second criteria
is that “the claimed invention also must qualify as patenteligible subject matter, i.e., the claim must not be directed to a
judicial exception unless the claim as a whole includes
additional limitations amounting to significantly more than the
58. See 566 U.S. 66, 73 (2012).
59. Id. at 76.
60. 35 U.S.C. § 101 (2019).
61. 35 USC § 101: Statutory Requirements and Four Categories of
Invention,
U.S.
PAT.
&
TRADEMARK
OFF.
(Aug.
2015),
https://www.uspto.gov/sites/default/files/101_step1_refresher.pdf.
62. See 2106 Patent Subject Matter Eligibility, U.S. PAT. & TRADEMARK
OFF.
(June
25,
2020,
6:21
PM),
https://www.uspto.gov/web/offices/pac/mpep/s2106.html#d0e197244.
63. Id.
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exception.”64 Courts have interpreted judicial exceptions to
include “abstract ideas, laws of nature, and natural phenomena
(including products of nature).”65 This is problematic for
diagnostic method patents because these terms typically cover
“the basic tools of scientific and technological work” such as
scientific principles and naturally occurring phenomena.66 For
example, a diagnostic test that locates the presence of a
naturally occurring antigen on the surface of a tumor is
considered to claim a “law of nature,” or in other words, a
judicially recognized exception.67
The USPTO’s judicial exceptions are at the crux of
diagnostic method claims patentability. Since malignant tumor
antigens are a product of nature, and products of nature are
unpatentable, the ability to secure a patent for a diagnostic test
that tests for the presence (or absence) of specific cancer
biomarkers has been thrown into disarray. Without the means
to acquire a patent, the monetary value of diagnostic testing has
diminished, and consequently, innovation has been hindered.
Also, importantly, instead of disclosing these inventions to the
public, as occurs in the quid pro quo of obtaining a patent,68
biotechnology companies and other scientific researchers who
have already found (and are continuing to find) new tumor
targets will likely keep their diagnostic tests as trade secrets,
preventing others from benefiting from those discoveries.69
V.

MAYO, MYRIAD, ALICE & THE
LOWER COURTS’ APPLICATION

Mayo was the first of three Supreme Court cases that
changed the rules of patent-eligibility for diagnostic method
claims. In Mayo, plaintiff Prometheus Laboratories, Inc.
(“Prometheus”), brought a claim for patent infringement against
defendants Mayo Clinic Rochester and Mayo Collaboratives
Services (collectively “Mayo”) after Mayo purchased
64. Id.
65. Id.
66. Id.
67. Id.
68. See Timothy R. Holbrook, Possession in Patent Law, 59 SMU L. REV.
123, 125 (2006).
69. See What Is a Trade Secret?, WORLD INTELL. PROP. ORG.,
https://www.wipo.int/tradesecrets/en/ (last visited Nov. 25, 2021).
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Prometheus’ diagnostic tests but then decided to sell a similar
version of its own.70 The diagnostic tests at issue were created
by Prometheus and assessed the dosages of thiopurine drugs
given to patients to treat autoimmune diseases such as
ulcerative colitis.71 Through administration of the test, doctors
were able to determine how a patient was metabolizing the
thiopurine compounds and then adjust the given dose to make
sure it was not too low or too high because if left unadjusted, it
could either cause harm or ineffectiveness for the patient.72 For
many years, Mayo bought and used these diagnostic tests.73
However, “in 2004 Mayo announced that it intended to begin
using and selling its own test––a test using somewhat higher
metabolite levels to determine toxicity . . . .”74 Prometheus then
brought a claim for patent infringement against Mayo.75
The Supreme Court ultimately invalidated Prometheus’
patents on the ground that they only “set forth laws of nature––
namely, relationships between concentrations of certain
metabolites in the blood and the likelihood that a dosage of a
thiopurine drug will prove ineffective or cause harm.”76 Because
the patents simply described those natural relations, and did not
add anything more or apply them in any way, they were not
eligible for patentability.77 Prometheus’ patents set forth a
three-step process that doctors could take in order to gather data
about a patient.78 These steps, the Court held, were not
“sufficient to transform the nature of the claim.”79 Unlike the
Court of Appeals for the Federal Circuit (“CAFC”), who believed
that this process passed under the “machine or transformation
test,” which would have brought the patents within the scope of
§ 101, the Court held that the steps were merely instructions
that added “nothing specific to the laws of nature other than
what [was] well-understood, routine, conventional activity, [and]
70. See Mayo Collaborative Servs. v. Prometheus Lab’ys, Inc., 566 U.S.
66, 75 (2012).
71. See id. at 73.
72. See id.
73. See id. at 75.
74. Id.
75. See id.
76. Id. at 77.
77. See id.
78. Id. at 78.
79. Id.
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previously engaged in by those in the field.”80 Further, the Court
emphasized that “upholding [these] patents would risk
disproportionately tying up the use of the underlying natural
laws, inhibiting their use in the making of further discoveries.”81
One year later, in Association for Molecular Pathology v.
Myriad, Genetics, Inc., the Supreme Court issued another
unanimous decision “invalidating patent claims directed toward
isolated DNA molecules derived from the human genome.”82 In
Myriad, defendant Myriad Genetics, Inc. (“Myriad”) “discovered
the precise location and sequence” of the BRCA1 and BRCA2
gene mutations and “obtained a number of patents based upon
its discovery.”83 As previously mentioned, these mutations are
associated with a dramatically increased risk of developing
breast cancer.84 Myriad was able to identify “the exact location
of the BRCA1 and BRCA2 genes” on two specific chromosomes,
and from there, could determine the genes’ typical nucleotide
sequence.85 This information “enabled Myriad to develop
medical tests that [were] useful for detecting mutations in a
patient’s BRCA1 and BRCA2 genes and thereby assess[]
whether the patient ha[d] an increased risk of cancer.”86 By
claiming patent rights over this DNA isolation, Myriad had “the
exclusive right to isolate an individual’s BRCA1 and BRCA2
genes.”87 When Myriad found out that other parties were
offering genetic testing for the BRCA gene mutations, they sent
these parties letters “asserting that the genetic testing infringed
Myriad’s patents.”88 These parties, which included doctors,
medical laboratories, and advocacy groups, responded by filing
suit “seeking a declaration that Myriad’s patents [were] invalid”
under § 101.89
80. Id. at 82.
81. Id. at 73.
82. Christopher M. Holman, Mayo, Myriad, and the Future of Innovation
in Molecular Diagnostics and Personalized Medicine, 15 N.C. J.L. & TECH. 639,
640 (2014).
83. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576,
579–80 (2013).
84. See id. at 583.
85. Id.
86. Id.
87. Id. at 585.
88. Id.
89. Id. at 586.
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Referencing its previous holding in Mayo, the Court again
held that “laws of nature, natural phenomena, and abstract
ideas are not patentable . . . Rather, ‘they are the basic tools of
scientific and technological work’ that lie beyond the domain of
patent protection.”90 The Court reasoned that since Myriad “did
not create or alter any of the genetic information encoded in the
BRCA1 and BRCA2 genes” and because “[t]he location and order
of the nucleotides existed in nature before Myriad found them,”
the patents were invalid.91 In sum, “[a] naturally occurring DNA
segment is a product of nature and not patent eligible merely
because it has been isolated . . . .”92 As in Mayo, the Court
determined that Myriad’s patents lacked an innovative method,
were well understood by scientists at the time the patents were
obtained, and did not involve any new application of the
knowledge.93 Although Myriad’s diagnostic test was agreed to
be immensely important for human health, the Court held that
without more, it was not enough to surpass the judicial exception
of “the laws of nature.”94
In Alice Corporation Pty. v. CLS Bank International, the
Supreme Court was asked to determine whether certain patents
disclosing a computer-implemented scheme for mitigating
“settlement risk” were patent-eligible under § 101.95 The
defendant Alice Corporation (“Alice”) claimed the patents
protected an invention that “facilitate[d] the exchange of
financial obligations between two parties by using a computer
system as a third-party intermediary.”96 This was done through
a computer system that instructed “financial institutions to
carry out ‘permitted’ transactions” based on “‘shadow’ credit and
debit records . . . that mirror[ed] the balances in the parties’ realworld accounts” at institutions such as banks.97 Based on these
“shadow” records, the intermediary was able to mitigate “the
risk that only one party [would] perform the agreed-upon

90.
91.
92.
93.
94.
95.
96.
97.

Id. at 589.
Id. at 590.
Id. at 576.
See id. at 595–96.
Id.
573 U.S. 208, 212 (2014).
Id. at 213.
Id.
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exchange.”98 Plaintiffs CLS Bank International and CLS
Services Ltd. (collectively “CLS Bank”) operated “a global
network that facilitate[d] currency transactions.”99 CLS Bank
filed suit against Alice, “seeking a declaratory judgment that the
claims at issue [were] invalid, unenforceable, or not
infringed.”100 Alice counterclaimed, “alleging infringement.”101
The Court, in line with Mayo and Myriad, invalidated the
patents under the judicially recognized exceptions to § 101,
which exclude “[l]aws of nature, natural phenomena, and
abstract ideas” from eligible subject matter.102 The Court held
that the patent claims at issue were directed to an abstract idea,
and thus were patent-ineligible.103 The Court reasoned that the
claims were drawn to “the concept of intermediated settlement”
and this concept was “a fundamental economic practice long
prevalent in our system of commerce.”104 It was determined that
the claims did nothing more than “recite the concept of
intermediated settlement as performed by a generic
computer.”105 This, the Court held, was equivalent to claiming
the “building blocks” of human ingenuity, which, if patentable,
“‘would risk disproportionately tying up the use of the
underlying’ ideas, and [were] therefore ineligible for patent
protection.”106 Because these patents merely claimed the
“building blocks,” as opposed to integrating them into a new and
useful inventive concept, they “fail[ed] to transform that
abstract idea into a patent-eligible invention.”107 Alice’s claims
could not be protected under § 101.
In light of these decisions, lower courts have attempted to
clarify what Mayo, Myriad, and Alice actually mean. The CAFC,
which has nationwide jurisdiction over patent suits, has
struggled to provide consistent guidance on the application of §
101 to its sister circuits, the district courts, and to the makers of
98. Id. at 214.
99. Id.
100. Id.
101. Id.
102. Id. at 216.
103. See id. at 219.
104. Id. (quoting Bilski v. Kappos, 561 U.S. 593, 611 (2010)).
105. Id. at 225.
106. Id. at 217. (quoting Mayo Collaborative Servs. v. Prometheus Lab’ys,
Inc., 566 U.S. 66, 73 (2012)).
107. Id. at 221.
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diagnostic method patents.108 For example, in 2016, the CAFC
vacated and remanded the District Court’s conclusion in Rapid
Litigation Management Ltd. v. CellzDirect, Inc.109
In
CellzDirect, the District Court granted summary judgment
invalidating certain patents for being “directed to a patentineligible law of nature” under § 101.110 The invention at issue
involved hepatocytes, which are a “type of liver cell that have a
number of attributes useful for testing, diagnostic, and
treatment purposes.”111 However, “fresh hepatocytes can only
be obtained from liver resections or non-transplantable livers of
organ donors, and their lifespan is short,” making their supply
limited and unpredictable.112 In order to preserve the supply,
they are often frozen at polar temperatures in a process called
“cryopreservation.”113
Yet scientists are well-aware that
cryopreservation has its drawbacks; mainly because hepatocytes
can only be frozen and thawed once before becoming too
damaged for further use.114 That was until Rapid Litigation
Management Ltd. (“IVT”) discovered a way for hepatocytes to
“surviv[e] multiple freeze-thaw cycles.”115 Upon this discovery,
IVT “developed an improved process of preserving hepatocytes”
and claimed it in a patent.116 In short, the process involved
thawing the hepatocytes, separating the viable from non-viable
ones, and refreezing only the viable cells, which showed to
exhibit “70% viability after the second thaw” upon later use.117
When CellzDirect, Inc. (“LTC”) began employing this improved
process in their own hepatocyte production, IVT sued for patent
infringement.118 LTC responded by filing “a motion for summary
judgment of invalidity under 35 U.S.C. §§ 101 and 112.”119 The

108. See Court Jurisdiction, U.S. CT. OF APPEALS FOR THE FED. CIR. (Nov.
24, 2021, 9:09 PM), http://www.cafc.uscourts.gov/the-court/court-jurisdiction.
109. Rapid Litig. Mgmt. v. CellzDirect, Inc., 827 F.3d 1042, 1044 (Fed.
Cir. 2016).
110. Id.
111. Id. at 1045.
112. Id.
113. Id.
114. See id.
115. Id.
116. Id.
117. Id.
118. See id. at 1046.
119. Id.
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District Court granted LTC’s motion on the ground that IVT’s
patent was invalid based on the “Supreme Court’s two-step
framework for determining patent eligibility.”120 At step one,
the patent was found to fall under the “law of nature”
exception.121 At step two, the patent was found to lack “the
requisite inventive concept” necessary to survive protection
under § 101.122 IVT appealed to the CAFC.123
Upon review, the CAFC vacated and remanded the District
Court’s judgment. The CAFC disagreed with the District Court’s
interpretation of what constitutes a “natural law” and, in doing
so, held that IVT’s claim was patent-eligible. Under step one of
the Supreme Court’s two-part test, the CAFC determined that
the patent at issue was not merely directed to a natural
discovery—the capability of the hepatocyte cells to survive
multiple freeze-thaw cycles—but instead claimed a “new and
improved way of preserving hepatocyte cells for later use.”124
The CAFC went further to “immediately distinguish[]” this case
from Supreme Court precedent, holding that the claimed
invention involved an innovative method of “producing a
tangible and useful result,” which falls outside of the “categories
of inventions that are ‘directed to’ patent-ineligible concepts.”125
Even if the claim did not survive step one, the CAFC held that
it would still pass under step two because claims that “‘improve[]
an existing technological process’ are sufficient to ‘transform[]
the process into an inventive application’ of the patent-ineligible
concept.”126 Either way, IVT’s invention constituted patenteligible subject matter under § 101.
This case was a huge sigh of relief for those who had still
been reeling from the outcomes of Mayo, Myriad, and Alice.
Even the former Commissioner for Patents at the USPTO,
Robert Stoll, agreed that the holding in CellzDirect was “very
heartening.”127 Some considered the decision a “significant
120. Id.
121. Id.
122. Id.
123. See id.
124. Id. at 1048.
125. Id. at 1048, 1050.
126. Id. at 1050 (quoting Alice Corp. Pty. v. CLS Bank Int’l, 573 U.S. 208,
223 (2014)).
127. Gene Quinn, Federal Circuit Gives Patent Eligibility Relief to Life
Sciences
Sector,
IPWATCHDOG
(July
5,
2016),
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turning point” from the Supreme Court’s broad interpretation of
patent-ineligible subject matter.128
For the companies,
scientists, and inventors interested in securing diagnostic
method patents, CellzDirect was the beacon of hope they had
been waiting for.
Those hopes were short-lived when, in 2019, the CAFC
decided Athena Diagnostics, Inc. v. Mayo Collaborative Services,
LLC. Athena Diagnostics (“Athena”) was the exclusive licensee
of a patent that covered methods for diagnosing rare
neurological disorders, such as myasthenia gravis (“MG”), by
detecting the binding of a patient’s autoantibodies to a protein
called muscle-specific tyrosine kinase (“MuSK”).129 Through a
process of iodination and immunoprecipitation (which were
undisputed as known techniques in the art at the time of the
invention), a sample of a patient’s bodily fluid was tested for the
binding of their autoantibodies to a MuSK epitope.130 The
sample was then tested for radioactivity, which was indicative
of MG.131 After Mayo Collaborative Services, LLC (“Mayo”)
“developed two or more competing tests that allegedly
practice[d]” the steps in Athena’s patent, “Athena accused Mayo
of patent infringement.”132 Mayo moved to dismiss, arguing that
the claims in Athena’s patent were invalid under § 101.133 The
District Court, citing Mayo, granted the motion, and Athena
appealed.134
The CAFC affirmed the District Court’s conclusion that
Athena’s patent claims were “directed to a law of nature.”135
Since the claims focused on the interaction between
autoantibodies in bodily fluid and a MuSK epitope, which was a
relationship that occurred naturally for some people with
MuSK-related neurological disorders, the CAFC, in a split
decision, determined that the patent fell within a judicial
https://www.ipwatchdog.com/2016/07/05/federal-circuit-patent-eligibility-lifesciences/id=70614/.
128. Id.
129. See Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, 915
F.3d 743, 746 (Fed. Cir. 2019).
130. See id. at 748.
131. See id.
132. Id. at 746.
133. See id. at 746.
134. See id. at 748.
135. Id.
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exception to § 101.136 In other words, the patent claims failed
under the first step of the Supreme Court’s two-step test for
patent-eligibility. Additionally, the CAFC held that Athena’s
claims failed under step two of the test because they merely
recited steps involving standard techniques in the art
(iodination and immunoprecipitation) and thus “lacked an
inventive concept.”137 Athena argued that the claims did provide
an inventive concept: “a new laboratory technique,” which
consisted of a sequence of steps “us[ing] man-made molecules” to
detect MuSK autoantibodies.138 Athena contended that because
there was no way to diagnose these rare neurological conditions
prior to their invention, their diagnostic method claims were
new, unobvious, and safe from patent-ineligibility.139 However,
the CAFC struck down these arguments as insufficient. 140
Distinguishing this case from CellzDirect, the CAFC held that
Athena’s invention, unlike IVT’s, did not use an unconventional
combination of steps, but instead performed “standard
techniques in a standard way to observe a newly discovered
natural law.”141 Without any technical improvement, the CAFC
held that the patent claims at issue could not be afforded any
protection under § 101.142 According to the CAFC, Athena had
failed to transform its patent-ineligible diagnostic method into a
patent-eligible invention. Athena subsequently requested a
rehearing en banc.143
The request was denied.144 In an eighty-six-page order,
which included “eight separate opinions” with four judges
“concurring with the en banc denial and another four dissenting
from the decision,” the conflicting opinions reflected that the
136. See id. at 748–49.
137. Id. at 748.
138. Id. at 750.
139. See id. at 754.
140. See id. at 752–53.
141. Id. at 754.
142. See Robert Stoll, What Happens to Diagnostic Method Patents After
Athena?,
IPWATCHDOG
(Mar.
6,
2019),
https://www.ipwatchdog.com/2019/03/06/diagnostic-method-patentsathena/id=107058/.
143. See Athena v. Mayo: A Splintered Federal Circuit Invites Supreme
Court or Congress to Step Up on 101 Chaos, IPWATCHDOG (July 8, 2019),
https://www.ipwatchdog.com/2019/07/08/splintered-federal-circuit-invitessupreme-court-review-athena-v-mayo/id=111055/.
144. See id.
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CAFC was not “divided so much on the issue of the importance
of Athena’s now invalidated patent claims but, rather, the
application of the U.S. Supreme Court’s [§] 101 jurisprudence
under Mayo.”145 For example, some concurring judges approved
of the Mayo subject matter framework, while others considered
it “harder to apply consistently” than the previously decided
patent-eligibility standards.146
On the other hand, some
dissenting judges considered Mayo to have been “mistakenly
enlarged” by the CAFC, causing the holding to be extended much
farther than it was intended to reach.147 However, both the
concurring and dissenting opinions agreed that it should be the
Supreme Court, not the CAFC, that “clarif[ies] Mayo’s judicial
exception to [the] laws of nature and its impact on patent claims
covering medical diagnostics.”148 Athena ultimately petitioned
for a writ of certiorari.149 Despite the CAFC’s cry for Supreme
Court intervention on the subject, the Court denied the request,
as further discussed below.
Why the apparent disconnect between the holding in Athena
as opposed to the holding in its predecessor CellzDirect?
Interestingly, the three Judges who decided CellzDirect, Chief
Judge Prost, Judge Stoll, and Judge Moore, were not all in
harmony on the issue presented in Athena. With Chief Judge
Prost concurring with the en banc denial of Athena, and both
Judge Stoll and Judge Moore dissenting from the denial of the
request, it is clear that there is still disagreement on the
interpretation of the Mayo framework, which is leading to
ongoing, inconsistent, and confusing jurisprudence.150
The implications of Athena rippled through the scientific
community and dashed the hopes of many stakeholders. Athena
was viewed by many as an inconsistent application of Supreme
Court precedent regarding the eligibility of diagnostic method
145. Id.
146. Id.
147. Id.
148. Athena Implores Supreme Court to Heed Federal Circuit’s
‘Unprecedented
Cry
for
Help’,
IPWATCHDOG
(Oct.
3,
2019),
https://www.ipwatchdog.com/2019/10/03/athena-implores-supreme-courtheed-federal-circuits-unprecedented-cry-help/id=114201/.
149. See Petition for Writ of Certiorari, Athena Diagnostics, Inc. v. Mayo
Collaborative Servs., LLC, 915 F.3d 743 (Fed. Cir. 2019) (No. 19-430).
150. See Athena v. Mayo: A Splintered Federal Circuit Invites Supreme
Court or Congress to Step Up on 101 Chaos, supra note 143.
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patent claims under 35 U.S.C. § 101. Without any consistent
rules as to what is and is not patentable, the makers of
diagnostic tests are left without any understanding as to which
of their innovations are patentable, thereby leading to a
disturbing effect on development. Noteworthy, in a footnote of
the CAFC opinion, the Athena majority admitted that they felt
compelled by the Supreme Court to render their decision in favor
of patent-ineligibility (“[o]ur precedent leaves no room for a
different outcome here”151), but “recognized that protection of
diagnostic methods would be good for society.”152 The dissent in
Athena noted that the CAFC’s “decisions on the patentineligibility of diagnostic methods are not consistent, and . . .
exacerbate the judge-made disincentives to development of new
diagnostic methods, with no public benefit.”153 For the millions
of people who could live better and healthier lives with the help
of these diagnostic tests, including the roughly 1.8 million
Americans who were diagnosed with cancer in 2019, innovation
is essential.154 Therefore, it is imperative that the courts provide
inventors and the other stakeholders of diagnostic method
patents with clarity and consistency on what is patent-eligible.
VI.

WHERE DOES THAT LEAVE US?

In the wake of Athena, many members of the intellectual
property community have come forward to express their
discontentment with the CAFC’s decision, and to ask the
Supreme Court for clarification on when diagnostic tests can be
patentable.155 For example, the Biotechnology Innovation
Organization (“BIO”), which is the principal trade association
representing the biotechnology industry both domestically and
abroad, issued a statement in August 2018 asking the Supreme

151. Athena Diagnostics, Inc., 915 F.3d at 764 n.4.
152. Stoll, supra note 142.
153. Athena Diagnostics, Inc., 915 F.3d at 757 (Newman, J., dissenting).
154. See Cancer Facts & Figures 2019, AM. CANCER SOC’Y,
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-factsfigures/cancer-facts-figures-2019.html (last visited Nov. 25, 2021).
155. See Tiffany Hu, Ex-Fed. Circ. Judge Decries ‘Fundamental Rift’ Over
Eligibility,
LAW360
(Nov.
1,
2019,
9:35
PM),
https://www.law360.com/ip/articles/1216107?utm_source=sharedarticles&utm_medium=email&utm_campaign=shared-articles.
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Court for guidance on the eligibility of nature-based products.156
BIO’s main concern was that ever since the Mayo decision was
rendered, “increasing uncertainty exists about the patenteligibility of biotechnological products that incorporate
naturally-occurring substances, and of methods using such
products in therapeutic [and] diagnostic . . . processes.”157 This
“unstable state of patent-eligibility jurisprudence” subsequently
affects modern biotechnologies “[a]s the developers of, and
investors in . . . [the] technologies” cannot predict the rules of
patent-eligibility for the claimed inventions.158 In other words,
with much risk and without the guarantee of reward,
investment in biotechnological innovation is inhibited due to the
unavailability of patent protection.159 Therefore, it is highly
important for biotechnology stakeholders to obtain clarification
regarding patent-eligibility for naturally occurring products
(such as diagnostic tests used to diagnose and treat cancer)
under 35 U.S.C. § 101.
In addition to the biotechnology stakeholders, even the
former CAFC Chief Judge Paul Michel, has publicly urged the
Supreme Court to grant certiorari to “clear up the ‘fundamental
rift’ within the” CAFC, which had caused “disharmony,
disagreement, and inconsistency” on the issue of patenteligibility.160 In his amicus brief, which was filed in support of
Athena’s petition for certiorari, Judge Michel went further to say
that the CAFC’s misinterpretation of Supreme Court precedent
has “created an unbounded and detrimental uncertainty in
biotechnology innovation” and the law now needs “correction.”161
Eleven other stakeholders, including “intellectual property or
patent law associations,” law professors, and “biotechnological,
pharmaceutical or medical disease associations,” also filed
amicus briefs in support of Athena.162 Nevertheless, on January
156. See Letter from Hans Sauer, Deputy Gen. Couns., VP for Intell.
Prop., for Biotechnology Innovation Org., to Hon. Andrei Iancu, Director of the
U.S. Pat. & Trademark Off. (Aug. 20, 2018) (on file with the USPTO).
157. Id.
158. Id.
159. See id.
160. Hu, supra note 155.
161. Id.
162. Leslie Kushner, Patenting Diagnostic Tests: Can We Expect
Changes?,
LAW
J.
NEWSLS.
(Jan.
2020)
http://www.lawjournalnewsletters.com/2020/01/01/patenting-diagnostic-tests-
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13, 2020, the Supreme Court denied certiorari.163
By denying certiorari the Supreme Court has left it up to
Congress to determine whether a change in § 101 should be fixed
by legislation.164 The Court solidified its stance on January 27,
2020, when it denied certiorari from three other petitioners who
were seeking a more “cohesive understanding” of § 101.165
Several CAFC Judges are in agreement with the idea of
legislative reform.166 For instance, Judge Kathleen O’Malley has
stated “I encourage Congress to amend the Patent Act once more
. . .” to clarify the § 101 standard.167 Under the congressional
action approach, “a bicameral, bipartisan group for Congress,
initiated by Senators Coon (D-DE) and Tillis (R-NC) [has]
released a draft bill to reform § 101 of the Patent Act.”168 This
draft includes “new text for § 101” and creates “a ‘practical
exception’ test to ensure that” patent-ineligible categories are
narrowly construed.169 Another important feature of this draft
is its “default position on eligibility.”170 Simply put, “to address
a concern that courts will seek to interpret the new statutory
language to salvage many of the existing judicial exceptions” the
bill has an “Additional Legislative Provisions” section that
“explicitly states that the ‘provisions of [§] 101 shall be construed
in favor of eligibility.’”171 This could be significant for reducing
the “challenges to patents under § 101.”172 Although the draft is
still “open to discussion,”173 it has “already been the subject of
hearing before the Intellectual Property Sub-Committee of the

can-we-expect-changes/.
163. See Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, 140
S. Ct. 855 (2020) (mem.) (No. 19-430).
164. See Kushner, supra note 162.
165. Dani Kass, Justices Reject 3 More Cases Challenging Alice, LAW360
(Jan. 27, 2020, 3:12 PM), https://www.law360.com/articles/1236828.
166. See Kushner, supra note 162.
167. Id.
168. Id.
169. Christopher P. King, Patent Eligibility Reform in Congress: Updates
on the Coons/Tillis Proposal, FENWICK: BILSKI BLOG (June 4, 2019),
https://www.bilskiblog.com/2019/06/patent-eligibility-reform-in-congressupdates-on-the-coons-tillis-proposal/#more-3974.
170. Id.
171. Id.
172. Id.
173. Id.
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Senate Judiciary Committee.”174 However, legislation is a slowmoving process, so it may be some time before the draft bill, if
ever, evolves into law.
If a legislative fix is attempted, guidance may be available
by looking at other countries’ guidelines on diagnostic method
patent-eligibility. For example, the European Patent Office
(“EPO”), which is responsible for grants of European patents for
the Contracting States to the European Patent Convention, has
some significant differences from the USPTO with regard to the
discovery and patentability of natural phenomenon that
American diagnostic method patent reform could benefit from.175
The USPTO and EPO are alike in that “the discovery of a
natural phenomenon is not patent eligible,” but the EPO
differentiates from the USPTO in that “a patentable invention
can derive from a practical use of that discovery . . . such as its
use in a method of diagnosis.”176 This means that “the discovery
of a naturally occurring correlation between a biomarker and a
disease can be put to a practical use in the form of a method for
diagnosing the disease” and thus be transformed into a
patentable invention.177 For diagnostic tests that use this same
pattern, such as those that test for specific biomarkers on tumor
cells in order to diagnose different kinds of cancer, the EPO’s
perspective on patent-eligibility is ideal. This is because
although these claims are objectionable under current USPTO
standards, they are patentable by EPO standards. By altering
the USPTO’s subject matter eligibility requirements to more
closely mirror Europe’s approach, American diagnostic method
patent claims may have more success under § 101.
Change is likely inescapable, but how far and wide that
change may reach is what remains to be seen. With a growing
demand for medical innovation, particularly related to the
development of immuno-oncology therapies for cancer
treatments, patent protection for diagnostic testing methods is
more necessary now than ever. These tests, which require a
174. Kushner, supra note 162.
175. See Hazel Ford, Patentability of Diagnostic Methods in Europe,
FINNEGAN
(Jan.
4,
2018),
https://www.finnegan.com/en/insights/blogs/european-ip-blog/patentability-ofmedical-methods-in-Europe-copy.html.
176. Id.
177. Id.

23

2021

PATENTING UNDER THE “LAWS OF NATURE”

219

large monetary investment (the average cost to develop a
diagnostic test in the United States “is $50 to $75 million”178),
are invaluable to the patients who can benefit from them.
Therefore, it is crucial to incentivize investment in these lifesaving diagnostic testing methods. In the absence of such
motivation, society could face “significant costs in human health,
lives, and medical care.”179 Immuno-oncology and the future of
modern cancer care may very well depend on the coming changes
to the subject matter eligibility analysis under 35 U.S.C. § 101.
VII.

THE NEED FOR LAW & MODERN
TECHNOLOGY TO CO-EXIST

The law is backward-looking; it focuses on case precedent
and prior judicial interpretation to establish principles and
maintain synonymy. On the other hand, science and technology
are forward-looking; they are constantly evolving and going
through cycles of revision as new information develops or comes
to the forefront. Put differently, science and modern technology
are quick to embrace change, while the law is much slower to
accept it. But the law, science, and modern technology
inevitably intersect, so they must find a way to exist together.
The Supreme Court initially sent shockwaves through the
intellectual property community in 2012 with its unanimous
decision in Mayo, where it narrowly interpreted patent-eligible
subject matter under 35 U.S.C. § 101. Eight years later, after a
fragmented application of Supreme Court precedent by the
CAFC, stakeholders in the biotechnology community are still
trying to understand the new patent-eligibility requirements.
With the Supreme Court’s January 2020 denial of Athena’s
recent petition for a writ of certiorari, it is clear that clarification
will likely not be coming from the judiciary. Instead, it may be
up to Congress to either amend or draft new legislation that will
provide biotechnology stakeholders with proper guidance on
what can and cannot be patented. With the rapid advances in
technology that are offering revolutionary new treatments for
the diseases in which there were few options only a short time
ago, it is important that a legislative fix comes sooner rather

178. Kushner, supra note 162.
179. Id.
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than later.
One of the most important groups of stakeholders who are
particularly anxious to see a change in USPTO patent-eligibility
under § 101 are the cancer patients themselves. As discussed in
this Note, immunotherapy has proven to “extend and save the
lives of many cancer patients” and “holds the potential to become
more precise, more personalized, and more effective than
current cancer treatments.”180 In a world where people are
forced to fight cancer every day, immunotherapy is the
breakthrough that patients, their families, their doctors, and
society as a whole has been hoping for. With immuno-oncology’s
power to transform modern cancer care, it is imperative that the
law finds a way to co-exist and indeed foster innovation in this
technology.
VIII.

ADDENDUM (WRITTEN APRIL 2020)

In light of the novel coronavirus (“COVID-19”) outbreak, a
highly contagious flu-like respiratory illness which was officially
declared a global pandemic by the World Health Organization
on March 11, 2020, the need for scientific innovation and new
medical discoveries (e.g., diagnostic tests, antiviral therapies,
and a vaccine) are absolutely crucial for the health of society.181
With over 1.8 million people diagnosed around the globe (over
500,000 in the United States alone) in the first five months,182
this contagion has caused the world to stop and “social distance”
until an effective remedy becomes available.183 This is yet
another, and even more pressing, example of why clarification
under 35 U.S.C. § 101 is necessary.
On March 23, 2020, the Naples Roundtable made one of the
first major pushes for a further explanation on subject matter
180. What Is Cancer Immunotherapy?, supra note 9.
181. See Coronavirus Disease 2019 (COVID-19) Situation Summary,
CDC,
https://www.cdc.gov/coronavirus/2019-ncov/casesupdates/summary.html (Feb. 25, 2020).
182. See COVID-19 Dashboard by the Center for Systems Science and
Engineering
(CSSE),
JOHNS
HOPKINS
U.
&
MED.,
https://coronavirus.jhu.edu/map.html (last visited Nov. 26, 2021).
183. Nell Greenfieldboyce, New Analysis Suggests Months of Social
Distancing May Be Needed to Stop Virus, NPR (Mar. 17, 2020, 4:03 PM),
https://www.npr.org/sections/health-shots/2020/03/17/817214311/newanalysis-suggests-months-of-social-distancing-may-be-needed-to-stop-virus.
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patent-eligibility since the COVID-19 pandemic first exploded
out of its epicenter in Wuhan, China.184 In a letter written to
Andrei Iancu, the Director of the USPTO, the Naples
Roundtable asked Iancu “to designate two Patent Trial and
Appeal Board opinions dealing with the patent eligibility of
medical inventions as precedential” because the COVID-19
pandemic undoubtedly “highlights the need for clarity.”185 In
both opinions, medical invention patent applications were found
to be patent-eligible under § 101.186 According to the Naples
Roundtable, this was significant, as “[t]he need for ongoing
medical discovery and innovation in the life sciences” is critical
in the face of the public health crisis that is the COVID-19
pandemic.187 As stated in the letter to Iancu, the pandemic “will
require innovation that should not be inhibited by a
misapplication” of § 101.188 In order to promote and incentivize
this innovation, “[d]esignating these decisions as precedential
will reduce the likelihood that [§] 101 will be misapplied and, in
turn, will . . . encourage a robust response” to the crisis.189 As
the world grapples with COVID-19, anxiously waiting for fastacting diagnostic testing kits, effective antiviral treatments, and
ultimately an FDA-approved vaccine, it is in the hands of the
USPTO to give the American people the relief they have been
desperately waiting for.
Additionally, the COVID-19 pandemic should further
motivate different groups of stakeholders to push harder for
legislative reform. As argued in this Note, with the Supreme
Court unwilling to grant certiorari to refine its previous
interpretations of Mayo, Myriad, and Alice, it is more likely that
Congress will be the vessel to provide the much-needed and more
unified understanding of what constitutes patent-eligible
subject matter under § 101. As the COVID-19 pandemic pushes
individual Americans and their families (including many on
Capitol Hill), the overall healthcare system, and the entire
184. See Dani Kass, Kappos Says Pandemic Calls for New Medical IP
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LAW360
(Mar.
23,
2020,
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PM),
https://www.law360.com/articles/1255666/kappos-says-pandemic-calls-fornew-medical-ip-precedent.
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global economy to its limits, this is the time for stakeholders to
push the legislative branch to act. Reform under § 101 of the
Patent Act is past due.
In conclusion, the world is currently facing very uncertain
and unprecedented times, as the COVID-19 pandemic continues
to sweep from its original outbreak in China to almost every
country on Earth.190 Due to the highly contagious nature of the
virus, paired with its zero-immunity tolerance level, it has
become immensely important for medical advances and
scientific innovation to have the proper flexibility to patent new
findings, targets, and therapies under 35 U.S.C. § 101. For
example, the ability to diagnostically test for the novel
coronavirus was one of the many hurdles recently faced in the
race to contain the pandemic.191 Further, when moving forward
to create a vaccine, one of the first steps will involve finding how
the virus initially enters the cell (subsequently infecting the host
and making it sick).192 Without the certainty of patent
protection under § 101 for the inventions required to address
this plague, stakeholders from both the public and private
sectors may be reluctant to invest in the innovation necessary to
fully address the pandemic. There has never been a more urgent
need to incentivize American innovation to solve this global
problem and save countless lives. The COVID-19 pandemic has
shone a spotlight on the need to address the subject matter
eligibility of these inventions and hopefully will stimulate a
rapid and thoughtful legislative response.
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